These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Therapeutic use of thymostimulin in HIV-seropositive subjects and with lymphadenopathy syndrome].
    Author: Carcò F, Guazzotti G.
    Journal: Recenti Prog Med; 1993 Nov; 84(11):756-64. PubMed ID: 8290787.
    Abstract:
    The Authors have carried out a study on the therapeutic effect of thymostimulin in HIV-positive subjects with lymphoadenopathy syndrome. Of the 140 selected patients, 70 were subjected to a treatment with thymostimulin (50 mg/die i.m. for 30 days + 50 mg/3 times a week i.m. in the second, third and fourth month + 50 mg/once a week i.m. in the fifth and sixth month) and of these patients, 60 completed the treatment and the estimated follow-up of twelve months. At the end of this period the following observations were made about the group treated: 1) improvement of the skin reaction to the Multitest (CMI) antigens in 66.7% of the cases, no changes in 30% of the cases and deterioration in 3.3% of the cases; 2) the total T-lymphocytes show an increase in the 6th month, remaining stable for the check-ups of the 9th and 12th months; 3) a significant increase of the CD4 lymphocytes in the 6th month with CD4/CD8 ratio close to the normal values, remaining the same even at the end of the follow-up; 4) during the study none of the treated patients developed opportunistic infections or HIV-related neoplasms. The results were also subjected by the Authors to statistical analyses between the two groups and therefore testify to a favourable effect of thymostimulin with an improvement in the laboratory indications taken into consideration and, above all, the quality of life.
    [Abstract] [Full Text] [Related] [New Search]